5IUATLD/WHO. The promise and reality of fixed-dose combinations with rifampicin[J]. International Journal of Tuberculosis and Lung Disease, 1994, 75 :180--181.
6World Heath Organization Tuberculosis Program. Treatment of tuberculosis guidelines for national programs[S]. Geneva: WHO, 1993.
7Morisky DE, Ang A, Krousel-Wood M, Ward H. Predictive Validity of a Medication Adherence Measure for Hypertension Control[J]. Journal of Clinical Hypertension 2008, 10(5):348 -354.
8Hong Kong Chest Service/British Medical Research Council. Acceptability,compliance,and adverse reactions when isoniazid, ri fampin,and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy[J]. Am Rev Respir Dis. 1989,140(6) : 1618-- 22.
9Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-report measure of medication adherence [J]. Med Care,1986,24:67- 74.
10Stettier C,Wandel S,Allemann S,et al.Outcomes associated with drug-eluting and bare-eluting stents:a collaborative network mata-analysis[J].Lancet,2007,307 (9591):937-948.
